Diffuse large B cell gastric lymphoma a rare disease: the effort to obtain scientific data in a multicenter, multinational retrospective trial  by Hamerschlak, Nelson
rev bras hematol hemoter. 2 0 1 6;3  8(3):186–187
www.rbhh.org
Revista Brasileira de Hematologia e Hemoterapia
Brazilian Journal of Hematology and Hemotherapy
Scientiﬁc Comment
Diffuse  large  B  cell  gastric  lymphoma  a rare
disease: the  effort  to  obtain  scientiﬁc  data  in a
multicenter, multinational  retrospective  trialNelson Hamerschlak ∗
Hospital Israelita Albert Einstein, São Paulo, SP, BrazilPrimary diffuse large B cell gastric lymphoma (DLBCGL)
accounts for approximately 1.5% of gastric neoplasms and 5%
of lymphomas.1 It represents 30–40% of the gastrointestinal
lymphomas and it is the most common extranodal site of
lymphoma. Generally, it occurs in patients between 50 and
60 years old and there is a slight male predominance.2
The most common symptom is epigastric pain but patients
can present with anorexia, nausea or vomiting, weight loss
and bleeding. Endoscopy and biopsy should be performed in
this kind of patient for the correct diagnosis. Some times pinch
biopsies may miss the diagnosis and larger samples have to
be attained.3–5 The use of endoscopic ultrasound and ﬂow
cytometry may achieve higher accuracy rates.2–5
An association of Helicobacter pylori with DLBCGL exists
and treatment to eradicate H. pylori has to be used in
the management of the disease when necessary.6 Very few
patients outside clinical trials are candidates for only H. pylori
therapy.
The Ann Arbor staging system is not always considered
as a tool in gastrointestinal lymphomas but there is limited
7consensus in the use of several other staging systems.
Treatment options for DLBCGL include surgery, radiation
therapy and chemoimmunotherapy with or without treat-
ment for H. pylori or a combination of the above. Surgery
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severe bleeding or obstruction. Nowadays, the majority of the
patients are treated with rituximab-based chemotherapy with
or without radiotherapy consolidation.8,9
The paper by Delamain et al., published in this issue of
the Revista Brasileira de Hematologia e Hemoterapia (RBHH),
addresses the main ﬁndings of DLBCGL in a multicenter retro-
spective study with 104 patients from three countries, Brazil,
Portugal and Italy. This kind of study is very important in rare
diseases since the majority of the recommendations are based
on data from case series, rather than large randomized trials.10
Different to the literature, the authors found a slightly
higher incidence in women, advanced stage and high-risk
age-adjusted international prognostic index (aaIPI) at diag-
nosis. The median age was in agreement with the current
literature and 13% of the patients were positive for H. pylori.
Few patients required surgery because of complications. The
patients were treated with rituximab with the cyclophos-
phamide, doxorubicin hydrochloride, vincristine sulfate and
prednisone regimen (R-CHOP) with or without radiotherapy de Ensino e Pesquisa Albert Einstein, Av. Albert Einstein, 627/520,
and the authors got impressive results considering not only
complete remission, but also overall survival rates. They also
contribute to the literature by identifying the aaIPI as a pre-
dictor factor for the survival of patients.
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